260 related articles for article (PubMed ID: 25387804)
1. The A3 adenosine receptor: history and perspectives.
Borea PA; Varani K; Vincenzi F; Baraldi PG; Tabrizi MA; Merighi S; Gessi S
Pharmacol Rev; 2015; 67(1):74-102. PubMed ID: 25387804
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of A2 and A3 adenosine receptor: a review of novel patented ligands.
Federico S; Spalluto G
Expert Opin Ther Pat; 2012 Apr; 22(4):369-90. PubMed ID: 22435652
[TBL] [Abstract][Full Text] [Related]
3. The A3 adenosine receptor: an enigmatic player in cell biology.
Gessi S; Merighi S; Varani K; Leung E; Mac Lennan S; Borea PA
Pharmacol Ther; 2008 Jan; 117(1):123-40. PubMed ID: 18029023
[TBL] [Abstract][Full Text] [Related]
4. Current Status in the Design and Development of Agonists and Antagonists of Adenosine A3 Receptor as Potential Therapeutic Agents.
Mailavaram RP; Al-Attraqchi OHA; Kar S; Ghosh S
Curr Pharm Des; 2019; 25(25):2772-2787. PubMed ID: 31333098
[TBL] [Abstract][Full Text] [Related]
5. Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.
Baraldi PG; Preti D; Borea PA; Varani K
J Med Chem; 2012 Jun; 55(12):5676-703. PubMed ID: 22468757
[No Abstract] [Full Text] [Related]
6. A
Jacobson KA; Merighi S; Varani K; Borea PA; Baraldi S; Aghazadeh Tabrizi M; Romagnoli R; Baraldi PG; Ciancetta A; Tosh DK; Gao ZG; Gessi S
Med Res Rev; 2018 Jul; 38(4):1031-1072. PubMed ID: 28682469
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological and therapeutic effects of A3 adenosine receptor agonists.
Fishman P; Bar-Yehuda S; Liang BT; Jacobson KA
Drug Discov Today; 2012 Apr; 17(7-8):359-66. PubMed ID: 22033198
[TBL] [Abstract][Full Text] [Related]
8. A3 adenosine receptor: pharmacology and role in disease.
Borea PA; Gessi S; Bar-Yehuda S; Fishman P
Handb Exp Pharmacol; 2009; (193):297-327. PubMed ID: 19639286
[TBL] [Abstract][Full Text] [Related]
9. The A3 adenosine receptor as multifaceted therapeutic target: pharmacology, medicinal chemistry, and in silico approaches.
Cheong SL; Federico S; Venkatesan G; Mandel AL; Shao YM; Moro S; Spalluto G; Pastorin G
Med Res Rev; 2013 Mar; 33(2):235-335. PubMed ID: 22095687
[TBL] [Abstract][Full Text] [Related]
10. Adenosine A3 Receptor: A promising therapeutic target in cardiovascular disease.
Nishat S; Khan LA; Ansari ZM; Basir SF
Curr Cardiol Rev; 2016; 12(1):18-26. PubMed ID: 26750723
[TBL] [Abstract][Full Text] [Related]
11. Molecular modeling study on potent and selective adenosine A(3) receptor agonists.
Dal Ben D; Buccioni M; Lambertucci C; Marucci G; Thomas A; Volpini R; Cristalli G
Bioorg Med Chem; 2010 Nov; 18(22):7923-30. PubMed ID: 20943397
[TBL] [Abstract][Full Text] [Related]
12. Topological sub-structural molecular design (TOPS-MODE): a useful tool to explore key fragments of human A3 adenosine receptor ligands.
Saíz-Urra L; Teijeira M; Rivero-Buceta V; Helguera AM; Celeiro M; Terán MC; Besada P; Borges F
Mol Divers; 2016 Feb; 20(1):55-76. PubMed ID: 26205409
[TBL] [Abstract][Full Text] [Related]
13. Investigational A₃ adenosine receptor targeting agents.
Koscsó B; Csóka B; Pacher P; Haskó G
Expert Opin Investig Drugs; 2011 Jun; 20(6):757-68. PubMed ID: 21457061
[TBL] [Abstract][Full Text] [Related]
14. Structural Probing and Molecular Modeling of the A₃ Adenosine Receptor: A Focus on Agonist Binding.
Ciancetta A; Jacobson KA
Molecules; 2017 Mar; 22(3):. PubMed ID: 28287473
[TBL] [Abstract][Full Text] [Related]
15. A(3) adenosine receptor: a plausible therapeutic target for cardio-protection in diabetes.
Nishat S; Shabir H; Azmi AS; Ansari HR
Recent Pat Cardiovasc Drug Discov; 2012 Apr; 7(1):59-70. PubMed ID: 22300387
[TBL] [Abstract][Full Text] [Related]
16. CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver.
Cohen S; Stemmer SM; Zozulya G; Ochaion A; Patoka R; Barer F; Bar-Yehuda S; Rath-Wolfson L; Jacobson KA; Fishman P
J Cell Physiol; 2011 Sep; 226(9):2438-47. PubMed ID: 21660967
[TBL] [Abstract][Full Text] [Related]
17. Suppression of inflammation response by a novel A₃ adenosine receptor agonist thio-Cl-IB-MECA through inhibition of Akt and NF-κB signaling.
Lee HS; Chung HJ; Lee HW; Jeong LS; Lee SK
Immunobiology; 2011 Sep; 216(9):997-1003. PubMed ID: 21514967
[TBL] [Abstract][Full Text] [Related]
18. Different efficacy of adenosine and NECA derivatives at the human A3 adenosine receptor: insight into the receptor activation switch.
Dal Ben D; Buccioni M; Lambertucci C; Kachler S; Falgner N; Marucci G; Thomas A; Cristalli G; Volpini R; Klotz KN
Biochem Pharmacol; 2014 Jan; 87(2):321-31. PubMed ID: 24161786
[TBL] [Abstract][Full Text] [Related]
19. Targeting A3 and A2A adenosine receptors in the fight against cancer.
Merighi S; Battistello E; Giacomelli L; Varani K; Vincenzi F; Borea PA; Gessi S
Expert Opin Ther Targets; 2019 Aug; 23(8):669-678. PubMed ID: 31189400
[No Abstract] [Full Text] [Related]
20. History and perspectives of A2A adenosine receptor antagonists as potential therapeutic agents.
Preti D; Baraldi PG; Moorman AR; Borea PA; Varani K
Med Res Rev; 2015 Jul; 35(4):790-848. PubMed ID: 25821194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
